![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd1158/MediaObjects/41573_2003_Article_BFnrd1158_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd1158/MediaObjects/41573_2003_Article_BFnrd1158_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd1158/MediaObjects/41573_2003_Article_BFnrd1158_Fig3_HTML.jpg)
References
Fossa, S. & Skovlund, E. Selection of Patients May Limit the Generalizability of Results from Cancer Trials. Acta Oncologica. 41, 131–137 (2002).
Stadtmauer, E. et al. Conventional dose chemotherapy compared with high dose chemotherapy plusautologous hematopoietic stem cell transplantation for metastatic breast cancer. N. Engl. J. Med. 342, 1069–1076 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Booth, B., Glassman, R. & Ma, P. Oncology's trials. Nat Rev Drug Discov 2, 609–610 (2003). https://doi.org/10.1038/nrd1158
Issue Date:
DOI: https://doi.org/10.1038/nrd1158
- Springer Nature Limited
This article is cited by
-
Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery
British Journal of Cancer (2020)
-
Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials
BMC Medical Research Methodology (2011)
-
A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials
BMC Medical Research Methodology (2011)
-
Do molecularly targeted agents in oncology have reduced attrition rates?
Nature Reviews Drug Discovery (2009)